Markets News
Latest stock market news and real-time market analysis. Track S&P 500, Nasdaq, and Dow Jones movements, sector rotations, and breaking market events.
LogProstyle Stock Retreats 30% Premarket After I-FLATZ Deal Rally
LogProstyle shares tumbled 30% in premarket trading, giving back gains from a 75% surge after announcing its I-FLATZ acquisition.
Vistance Shares Slip 42.7% Premarket on $5 Payout, $150M Buyback Expansion
Vistance (VISN) shares dropped 42.7% premarket after a $5 special dividend and $150M buyback expansion. Adjusted for the payout, value is slightly higher, but margin pressures persist.
BioXcel Therapeutics Files Chapter 11; Shares Plunge 62%
BioXcel Therapeutics (BTAI) filed for Chapter 11 bankruptcy, sending shares down 62.4% to $0.27. The company's liabilities ($100M-$500M) far exceed its assets ($10M-$50M), leaving common equity subordinate.
Biohaven Shares Slide 5% as Raymond James Slashes Target on Opakalim Deal
Biohaven (BHVN) shares dropped 4.9% to $16.12 after Raymond James cut its price target to $30 from $50, citing the opakalim licensing deal that brings $400M cash but reduces upside.
Braskem ADRs Jump 10.8% on Petrobras Credit Boost
Braskem ADRs surged 10.8% after Petrobras increased its supplier credit line to R$2.35 billion, providing working capital as the company restructures $10.9 billion in debt.
FTSE Edges Higher as Miners Rally, Defence Stocks Slip
Miners and 3i lift FTSE 100, but defence names slide as investors await Fed's Warsh speech. Mid-caps also firm.
DraftKings Slides 2.3% as NFL Renews Rivalry with FanDuel Ahead of $30B Season
DraftKings shares dropped 2.3% after the NFL renewed partnerships with FanDuel and added Fanatics. The league's $30 billion betting season begins September 9.
Celularity Shares Surge 138% on $300M MuseCell Manufacturing Forecast
Celularity (CELU) shares jumped 138.5% after projecting $300M in MuseCell manufacturing revenue, but the company faces cash constraints and going-concern doubts.
Intel Gains 4.4% as Nvidia's Optimistic Forecast Boosts AI Chip Sentiment
Intel shares climbed 4.4% to $92.09 following Nvidia's bullish revenue forecast, which eased concerns about AI infrastructure spending. However, the stock remains below its recent $95 equity offering price.
Sarepta Surges 13% Despite Delay in Elevidys Safety Trial
Sarepta's stock rallied 13% despite a five-month delay in its Elevidys safety study, as investors weigh the new trial site against weak sales and high short interest.